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ABSTRACT 
Rationale and objective: The impact of Tolvaptan on health-related quality-of-life 
(HRQoL) in autosomal dominant polycystic kidney disease (ADPKD) patients is 
unknown. To address this knowledge gap, we studied patient-reported health-related 
quality of life (HRQoL) in patients enrolled in the Bern ADPKD registry. 
Study design: Prospective cohort study. 
Settings and participants: Inclusion criteria were age ≥18y, clinical diagnosis of ADPKD 
and informed consent. The main exclusion criterion was need for kidney replacement 
therapy.  
Outcome: HRQoL was assessed with the standardized Kidney Disease Quality of Life 
Short Form (KDQOL-SF) questionnaire at start of the study (baseline) and after one year 
(follow-up). The KDQOL-SF has two parts: a generic Short Form-36 instrument with 
eight subscores and two summary scores, and a kidney disease-specific instrument to 
assess health concerns. Higher scores indicate better HRQoL. The influence of Tolvaptan 
treatment on HRQoL and on kidney-specific health concerns was analysed using analysis 
of covariance (ANCOVA), adjusting for HRQoL and health concerns before start of the 
study, sex and age.  
Results: In 38 of 121 registry patients, Tolvaptan treatment was initiated. Within the first 
three months, treatment had to be discontinued in six patients (16%) due to aquaretic side 
effects (N=4, 11%) or elevated liver enzymes (N=2, 5%), and a dose reduction was 
necessary in eight patients (21%). We included 98 patients (30 with and 68 without 
Tolvaptan treatment) in the analysis for which baseline and 1-year follow-up data were 
available. At follow-up, and after adjusting for baseline scores, sex and age, HRQoL and 
Page 3 of 26 
 
kidney-specific health concerns were not influenced by Tolvaptan treatment, except for 
“patient satisfaction” which was increased. 
Limitations: Observational study design, monocentric study at tertiary referral hospital, 
almost exclusively white study population, grant support by Otsuka Pharmaceuticals. 
Conclusions: Our results indicate that Tolvaptan does not significantly affect HRQoL in 
ADPKD patients who tolerate treatment beyond the first three months of therapy. 
 
Index words: ADPKD, Tolvaptan, HRQoL, quality of life. 
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INTRODUCTION 
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common 
inherited kidney disease worldwide, occurs in all ethnic groups and accounts for up to 10 
% of patients with end-stage renal disease (ESRD) 1. Mutations in PKD1 and PKD2 
genes account for the overwhelming majority of ADPKD cases 2. 
The disease is characterized by a progressive enlargement of the kidneys due to 
cyst growth, resulting in chronic flank pain, abdominal fullness and in advanced cases 
early satiety. Kidney cysts are associated with arterial hypertension and urological 
complications such as cyst hemorrhage, gross hematuria, recurrent urinary tract infections 
and nephrolithiasis. ADPKD manifestations are not restricted to the kidneys; well-known 
extrarenal manifestations include intracranial aneurysms that may cause fatal bleeding 
due to rupture, liver cysts, colonic diverticular disease, abdominal hernias and cardiac 
valve abnormalities. 
Due to its progressive nature, the associated co-morbidities and that it is 
hereditary, ADPKD imposes a significant burden on affected patients. The association of 
patient-reported health-related quality-of-life (HRQoL) with ADPKD disease severity 
markers has been assessed in several previous studies, but results were inconclusive, at 
least partially attributed to small sample size, patient selection or use of generic HRQoL 
instruments only 3-7. A recent meta-analysis of nine studies employing standardized 
HRQoL assessments with the generic SF-36 questionnaire encompassing 1623 patients 
concluded that overall physical and mental component scores were significantly reduced 
in ADPKD patients compared to the reference population, even after age correction 8. 
Interestingly, larger liver volume, but not eGFR or total kidney volume displayed a 
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significant negative correlation with age-corrected HRQoL in ADPKD patients. In 
support of these findings, treatment of severe polycystic liver disease by somatostatin 
analogues but not with placebo improved HRQoL in a pooled analysis of two 
randomized, placebo-controlled trials 9. 
Recently, Tolvaptan, an orally active, non-peptide selective arginine vasopressin 
V2R antagonist has been approved for the treatment of ADPKD in many countries, 
including Switzerland. In two randomized, double-blind, controlled phase III trials, 
TEMPO 3:4 and REPRISE, respectively, Tolvaptan lowered the increase in total kidney 
volume (TEMPO 3:4 only) and kidney function decline (both studies) compared to 
placebo 10, 11. However, a high frequency of aquaresis-related adverse events (thirst, 
polydipsia, polyuria, nocturia) was noted in these clinical trials. Although regular HRQoL 
assessment in patients with Tolvaptan treatment was advocated in recent treatment 
guidelines 12, the impact of the drug on patient’s HRQoL has not been studied 
systematically and thus is largely unknown at the moment. 
To address this knowledge gap, we compared baseline (treatment-naïve) and 
follow-up (with or without Tolvaptan treatment) HRQoL using the KDQOL-SF 
questionnaire in participants of the Bern ADPKD registry. 
METHODS 
Study population 
The Bern ADPKD registry is a prospective, observational cohort of ADPKD 
patients at the Department of Nephrology and Hypertension at the Bern University 
Hospital, Bern, Switzerland. Inclusion criteria are: (1) ADPKD based on the criteria by 
Ravine et al. 22; (2) minimum age of 18 years; (3) written informed consent. Need for 
kidney replacement therapy was an exclusion criterion. The Bern ADPKD registry 
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adheres to the Declaration of Helsinki and was approved by the ethical committee of the 
Kanton of Bern (approval # BE 124/15). Between October 2015 and March 2019, 121 
patients were included in the Bern ADPKD registry. In 98 of 121 registry participants, 
baseline and one-year follow-up data were available as of March 2019. 
Tolvaptan treatment 
Tolvaptan became available for patients in Switzerland on November 1 2016. 
Treatment is reimbursed by health care insurance companies if the following criteria are 
met: i) age ≥ 18 years, ii) typical class I ADPKD, iii) CKD stages I – III, iv) total kidney 
volume ≥ 750 ml and v) evidence of rapid progression. Rapid progression is defined as 
Mayo class 1C-1E or eGFR decline ≥ 5 ml/min per 1.73 m2 or growth of kidney volume 
> 5 %/year or truncating PKD1 mutation and a PROPKD-Score >6 23. The decision on 
Tolvaptan treatment initiation was left to the responsible investigator, always a board-
certified Nephrologist. Treatment was always initiated with the lowest split dose regimen 
of 45/15 mg and uptitrated in monthly intervals to 60/30 mg and ultimately to 90/30 mg, 
as tolerated by the patient. 
Data collection and measurements 
Patients in the registry are seen at baseline and yearly thereafter. At each visit, 
patients undergo a physical examination including measurement of height and weight, 
office and 24-hour blood pressure measurements. Office blood pressure measurements 
were done in supine position after at least 5 minutes of rest using the oscillometric 
method. At baseline, total kidney volume (TKV) was determined by MRI using the 
ellipsoid method and patients were subclassified according to height-adjusted TKV 
(HtTKV) ranges for age into Mayo classes 1A-E 24. Standardized blood and urine 
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analysis, including a 24-hour urine collection, are conducted at baseline and then 
annually. All blood analyses were performed after at least a 6 hour fast in the morning 
before noon. Urine and blood analyses were performed at the Central Laboratory of the 
Bern University Hospital, Bern, Switzerland using standard laboratory methods. The 
creatinine-based CKD-EPI 2009 equation was used to estimate the glomerular filtration 
rate eGFRcr 25.  
Diabetes was defined as reported, treated, or fasting glycemia ≥7 mmol/L. 
Hypertension was defined as either systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg, or 
use of antihypertensive medications. 
Quality of life assessment 
At baseline and then at each yearly visit, the kidney disease quality of life 
questionnaire KDQOL-SF 1.2  was used to assess patient-reported health-related quality 
of life. KDQOL-SF is an instrument developed for individuals with kidney disease by the 
RAND corporation (https://www.rand.org/health-care/surveys_tools/kdqol.html) and 
consists of 36 items that provide a generic score and an overall health rating item (SF-36) 
as well as 43 kidney-disease targeted items 18. The SF-36 consists of 36 items (questions) 
that measure eight health-related subscales: physical functioning (PF), role limitations 
caused by physical health problems (RP), role limitations caused by emotional health 
problems (RE), social functioning (SF), emotional well-being/mental health (MH), bodily 
pain (BP), vitality (energy/fatigue; VT) and general health perceptions (GH) and two 
summary scores: physical component summary (PCS) and mental component summary 
(MCS). Responses were scored into T-scores, with a mean of 50, SD of 10 and a range of 
0–100, based on age-stratified Swiss normative population assessed during 2015-2016 
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(N=1209). Higher scores reflect better HRQoL 13, 26-28. The kidney-disease targeted items 
include symptom/problem, effects of kidney disease, burden of kidney disease, work 
status, cognitive function, quality of social interaction, sexual function, sleep, social 
support, patient satisfaction and an overall health item and were scored (0–100) a higher 
score representing better quality-of-life 14. One question from the KDQOL-SF (related to 
dialysis) was omitted because our patients were not on dialysis. The KDQOL-SF has 
been used previously in health-related quality of life studies in patients with CKD not on 
dialysis 4, 29, 30. 
Statistical analysis 
Categorical data are described by number of individuals N (%), continuous 
variables are described by their mean and standard deviation or by their median and 25th-
75th percentile. All statistical tests were two-sided and a p value <0.05 was considered 
statistically significant. The means of the eight subscales of the SF-36 and the PCS and 
MCS were used to compare ADPKD patients to Swiss norms, between different 
treatment groups and time points by calculating exact confidence intervals. 
Questionnaires with >50% missing data in subscales or compound scales were excluded 
from statistical analysis. Analysis of covariance (ANCOVA) was used to examine the 
impact of Tolvaptan treatment on HRQOL and on kidney disease-specific health 
concerns after one year of follow-up31. For each scale (of HRQoL and of kidney disease-
specific health concerns), we ran an ANCOVA. The models included the score of the 
scale at follow-up as dependent variables and the score of the same scale at baseline as 
independent variables,, Tolvaptan treatment status (yes/no), sex and age at follow-up 
(continuous, in years) regardless of their significance. If meaningful interaction was 
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present, we included second level interaction terms in the models. All statistical analyses 
were conducted using Stata, release 15.1 (College Station, TX, USA: StataCorp LLC) 15 
and the R software, version 3.2.2 32. We used the Stata package coefplot for plotting 
mean differences in HRQoL and kidney-specific health concerns between patients treated 
with vs. those not treated with Tolvaptan 33. 
RESULTS 
Characteristics of the study population 
The Bern ADPKD registry is a prospective, observational cohort of ADPKD 
patients without kidney replacement therapy at the Department of Nephrology and 
Hypertension at the Bern University Hospital, Bern, Switzerland. Between October 2015 
and March 2019, 121 ADPKD patients were included in the Bern ADPKD registry (Fig. 
1). In the final analysis, we included 98 registry participants for whom baseline and at 
least one-year follow-up HRQoL data were available. Baseline characteristics of the 
overall study population as well as separated in patients with (N = 30) and without (N = 
68) future Tolvaptan treatment are shown in Table 1. Patients with future Tolvaptan 
treatment had a median age of 45.8 years, were more often men and had higher total as 
well as height-adjusted kidney volumes than patients without future Tolvaptan treatment.  
Tolvaptan treatment has been initiated in 38 of 121 (31.4 %) registry patients thus far. 
Tolvaptan was discontinued within the first three months of treatment in four patients due 
to aquaretic side effects (10.5 %) and in two patients due to elevated liver function tests 
(5.3 %). In the 32 patients remaining on Tolvaptan treatment, 24 patients (75 %) were on 
the maximal dose 90/30 mg, in eight patients (25 %), a dose reduction to 60/30 (N = 6) or 
45/15 mg (N = 2) was necessary. 
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HRQoL of Swiss ADPKD patients – comparison to general population and impact 
of Tolvaptan treatment 
General HRQoL was assessed by SF-36 subscales (physical functioning, role-
physical, bodily pain, general health, energy/vitality, social functioning, role-emotional, 
mental health), and two summary scores: Physical Component Summary (PCS) and 
Mental Component Summary (MCS). Raw scores were transformed into T-scores 
(mean=50, SD=10, range 0-100) stratified by age, using contemporaneous Swiss general 
population norms 13. ADPKD patients without future Tolvaptan treatment had lower 
scores in physical functioning and general health, but scored similar as the general 
population in all other subscales and summary scales of the SF-36 (Table 2). In contrast, 
ADPKD patients with future Tolvaptan treatment had a better score in bodily pain (i.e. 
less bodily pain) and a higher PCS than the general population.  
After one year follow-up, patients with Tolvaptan treatment continued to score 
better in bodily pain and had a higher score in physical functioning than the general 
population (Table 2). Patients without Tolvaptan treatment continued to score lower in 
general health than the general population, but scored higher than the general population 
in bodily pain at one-year follow-up. 
Results from analysis of covariance (ANCOVA) showed that Tolvaptan treatment 
status did not affect HRQoL after one year of follow-up after adjusting for HRQoL at 
baseline, sex and age (Table 3, Fig. 2). As expected, we found a strong association of 
HRQoL at baseline on HRQoL at follow-up.  
In a next step, we analyzed the kidney disease-specific health concerns, for which 
no normative data from the general population exist. Kidney disease-specific health 
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concerns (symptoms/problems, effects of kidney disease, burden of kidney disease, work 
status, cognitive function, quality of social interaction, sexual function, sleep, social 
support, patient satisfaction and overall health) were scored (0–100), with a higher score 
representing better health perception14. In the analyses of covariance models, after 
adjusting for baseline scores of health concern, sex and age, Tolvaptan treatment had no 
influence on health concerns at follow-up, except for patient satisfaction, which was 
better in patients treated with Tolvaptan (Table 4, Table 5,  Fig. 3). Higher scores of 
kidney-specific health concerns were significantly associated with higher scores at 
baseline. 
DISCUSSION 
Previous HRQoL assessments in ADPKD patients have been mostly cross-
sectional 9. Only for laparoscopic cyst decortication 15 and lanreotide treatment in patients 
with advanced polycystic liver disease, HRQoL was assessed prospectively 16, 17. Our 
study represents the first report of a systematic HRQoL assessment of Tolvaptan 
treatment on HRQoL in ADPKD patients. For HRQoL assessments in our cohort of 98 
ADPKD patients, we used the well-validated KDQOL-SF questionnaire that contains the 
generic SF-36 and 43 kidney-disease targeted items 18. While the generic SF-36 part has 
been used in several previous studies with ADPKD patients 3-8, 15-17, 19, the more extensive 
and thus more informative kidney-disease item part of the KDQOL-SF questionnaire has 
only been employed in one previous study 4. The generic SF-36 part allowed us to 
compare HRQoL outcomes in AKPKD patients with the Swiss general population 13. Our 
results demonstrate that overall self-reported HRQoL in our cohort of Swiss non-dialysis 
ADPKD patients is similar to the general population, as reported previously in other 
cohorts 3, 6, 19. However, HRQoL assessments in ADPKD patients yielded conflicting 
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results in the past and some studies, including a recent meta-analysis, reported 
significantly reduced HRQoL in non-dialysis dependent ADPKD patients 4, 8, 16, 17, 20. 
These differences may be due to variability in patient demographics, co-morbidities, 
degree of liver involvement and CKD stage of patients studied. In support of this, our 
observation that patients with future Tolvaptan treatment had a higher PCS score at 
baseline compared to the general population may be due to selection bias. Only patients 
with relatively preserved health without significant comorbidities are candidates for a 
Tolvaptan prescription. Obviously, up-to-dateness and representativeness of normative 
data from the general population will also significantly influence results. Normative 
values of the general population used for our study were derived from a contemporaneous 
and representative sample of the Swiss population, supporting the validity of our results 
[13].  
The systematic inclusion of all ADPKD patients treated at our site in the ADPKD 
registry reveals that 11% of patients elected to suspend treatment with Tolvaptan due to 
aquaretic side effects, similar to the discontinuation rate observed in the TEMPO 3:4  
trial 10. In an additional two patients (5 %), Tolvaptan had to be withdrawn due to 
elevated liver enzymes. All treatment cessations occurred within the first three months of 
treatment. Prospective HRQoL assessment in patients continuing Tolvaptan beyond the 
first three months of treatment indicates that the therapy is well tolerated without 
significant impact on overall physical or mental health scores, as assessed by the generic 
SF-36 part of the KDQOL-SF questionnaire. Patient-reported feedback evaluation of 
kidney-disease specific items revealed increased patient satisfaction at follow-up. The 
reasons for increased satisfaction in Tolvaptan-treated patients can only be speculated. 
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Positive selection of patients that tolerated this novel disease-modifying drug in the 
analysis and close patient-physician relationship due to monthly visits for liver function 
tests are likely causes. Surprisingly, however, neither the categories work status nor sleep 
were affected by Tolvaptan treatment. 
Our study has a number of limitations. First, because of the limited number of 
patients on Tolvaptan therapy, we may have missed effects due to the lack of statistical 
power. Likewise, the number of follow-up questionnaires available from patients who 
stopped Tolvaptan was too low for a sub-set analysis. Larger studies are needed to 
definitively establish the impact of Tolvaptan treatment on HRQoL in ADPKD patients. 
Second, our results apply to a selected group of patients who tolerated long-term 
treatment of Tolvaptan. Importantly, however, we included all patients with reduced dose 
Tolvaptan in our analysis who continued treatment beyond the first three months. In all of 
the eight patients on submaximal Tolvaptan dose, dose reductions were necessary 
because of aquaretic side effects. Third, selection bias may have caused differences 
observed in both general and kidney-specific HRQoL scores between patients with and 
without Tolvaptan treatment. Fourth, we may have missed important aspects of HRQoL 
in our study population because we did not use an ADPKD-specific HRQoL instrument. 
The ADPKD impact scale HRQoL instrument was developed only after our study was 
initiated 21. 
In summary, our study reveals that HRQoL in Swiss ADPKD patients is 
comparable to HRQoL in the general Swiss population. Furthermore, our results indicate 
that Tolvaptan does not significantly affect HRQoL in ADPKD patients who tolerate 
treatment beyond the first three months of therapy.  
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FIGURE LEGENDS 
 
Figure 1. Overview of patients with and without Tolvaptan treatment in the Bern 
ADPKD registry. Tolvaptan treatment was started in 38 of 121 ADPKD registry patients 
(n = 31.4 %), therapy was stopped within the first three months of treatment in 6 patients 
(n= 15.8 %) due to aquaretic side effects or elevated liver function tests (LFTs). Eight 
patients (n= 21.1 %) did not tolerate the maximal Tolvaptan dose (90/30 mg) and a dose 
reduction to 60/30 mg or 45/15 mg was necessary. In 68 patients without Tolvaptan 
treatment and 30 patients with Tolvaptan treatment, baseline and 1 year follow-up 
HRQoL data were available for analysis. 
 
Figure 2. Change in HRQoL after one year of Tolvaptan treatment vs. no Tolvaptan 
treatment. Abbreviations: PF, physical functioning; RP, role limitations caused by 
physical health problems; RE, role limitations caused by emotional health problems; SF, 
social functioning; MH, emotional well-being/mental health; BP, bodily pain; VT, 
vitality (energy/fatigue); GH, general health perceptions; PCS, physical component 
summary; MCS, mental component summary. Filled diamonds indicate differences in 
HRQoL T-scores for ADPKD patients treated with Tolvaptan vs. those not treated with 
Tolvaptan (reference) derived from multivariable linear regression involving HRQoL as 
dependent and Tolvaptan status, sex and age as independent variables. A positive 
difference indicate better HRQoL in patients with Tolvaptan vs those without Tolvaptan. 
Capped spikes indicate 95% confidence intervals. 
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Figure 3. Change in kidney-specific health concerns after one year of Tolvaptan 
treatment vs. no Tolvaptan treatment. Abbreviations: symptom, symptom/problem; 
effect, effects of kidney disease; burden, burden of kidney disease; work, work status; 
cognition, cognitive function; interact, quality of social interaction; sexfunction, sexual 
function; support; social support; satisfaction, patient satisfaction; health, overall health.  
Filled diamonds indicate differences in health concern scores for ADPKD patients treated 
with Tolvaptan vs. those not treated with Tolvaptan (reference) derived from 
multivariable linear regression involving health concerns as dependent and Tolvaptan 
status, sex and age as independent variables. A positive difference indicate better scores 
in health concerns of patients with Tolvaptan vs those without Tolvaptan. Capped spikes 
indicate 95% confidence intervals.  
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Table 1 | Characteristics of the study population at baseline visit.  
Characteristics 
  
N All patients 
  
N No Tolvaptan 
  
N Tolvaptan 
  
p-value 
Women 
  
55 56.1% 
  
44 64.7% 
  
11 36.7% 
  
0.02 
Age, years 
  
98 45.8;37.6-52.7 
  
68 45.95;35.4-57.6 
  
30 45.8;40.2-49.7 
  
0.94 
Body mass index, kg/m2 
  
97 24.7;22.2-27.5 
  
68 24.6;21.8-27.6 
  
29 24.7;22.3-27.1 
  
0.89 
Hypertension 
  
74 76.3% 
  
49 72.1% 
  
25 86.2% 
  
0.22 
Antihypertensive medication intake 
  
62 63.9% 
  
41 60.3% 
  
21 72.4% 
  
0.36 
       ACE inhibitors or sartans  
  
54 55.7% 
  
33 48.5% 
  
21 72.4% 
  
0.05 
       Calcium channel blockers 
  
21 21.6% 
  
14 20.6% 
  
7 24.1% 
  
0.91 
       Beta blockers  
  
9 9.3% 
  
6 8.8% 
  
3 10.3% 
  
1 
       Diuretics 
  
20 20.6% 
  
14 20.6% 
  
6 20.7% 
  
1 
Diabetes 
  
2 2.1% 
  
2 2.9% 
  
0 0.0% 
  
0.88 
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m2 BSA 
  
98 70.9;47.1-93.4 
  
68 78.1;44.5-97.8 
  
30 64.4;49.9-90.7 
  
0.39 
eGFR subgroups 
  
    
  
    
  
    
  
  
         ≥90 
  
27 27.6% 
  
19 27.9% 
  
8 26.7% 
  
0.04 
         60-89 
  
36 36.7% 
  
27 39.7% 
  
9 30.0% 
  
0.003 
         30-59 
  
24 24.5% 
  
15 22.1% 
  
9 30.0% 
  
0.22 
         15-30 
  
9 9.2% 
  
5 7.4% 
  
4 13.3% 
  
0.74 
         ≤15 
  
2 2.0% 
  
2 2.9% 
  
0 0.0% 
  
 - 
Total kidney volume (TKV), mL 
  
84 1220;672-2171 
  
56 871;529-1662 
  
28 1743;1225-2329 
  
<0.001 
Height-adjusted TKV (htTKV), mL/m 
  
84 731;396-1255 
  
56 526;340-1123 
  
28 950;735-1439 
  
0.002 
ADPKD Mayo classification available 
  
84 85.7% 
  
56 82.4% 
  
28 93.3% 
  
0.22 
ADPKD Mayo classification subgroups 
  
    
  
    
  
    
  
  
       Class 1A 
  
5 6.0% 
  
5 8.9% 
  
0 0.0% 
  
 - 
       Class 1B 
  
27 32.1% 
  
26 46.4% 
  
1 3.6% 
  
<0.001 
       Class 1C 
  
33 39.3% 
  
19 33.9% 
  
14 50.0% 
  
0.38 
       Class 1D 
  
13 15.5% 
  
3 5.4% 
  
10 35.7% 
  
0.05 
       Class 1E 
  
6 7.1% 
  
3 5.4% 
  
3 10.7% 
  
1 
Tolvaptan intake 
  
30 30.6% 
  
 -  - 
  
 -  - 
  
 - 
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Table 1 footnote: Categorical variables are expressed as number of participants N (%), continuous variables are expressed as 
median and 25th-75th percentile. Abbreviations: BP, blood pressure; ACE inhibitor, angiotensin-converting-enzyme inhibitor; 
BSA, body surface area; eGFR, estimated glomerular filtration rate. 
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Results from multivariable linear regression. Abbreviations: CI, confidence interval; N, number;  
aMean T-scores with 95 % CIs are standardized to age-stratified Swiss general population norms with a mean of 50 and a standard deviation of 10. Higher 
scores indicate better HRQoL. Bold numbers indicate deviation from general population with a probability of >95%. 
  
Table 2: Mean SF-36 T-scores of AKPKD patients with and without Tolvaptan treatment at baseline and follow-up  
 
  
Time point 
Tolvaptan   No Tolvaptan   
  
N Mean scores  (95% CI)a   N 
Mean scores  
(95% CI)a   
Subscales 
Physical functioning Baseline 30 51.8 (49.8; 53.9) 68 46.9 (43.9; 49.9) 
Follow-up 23 52.6 (51.3; 53.9) 45 49.9 (47.7; 52.1) 
              
Role physical Baseline 29 53.2 (49.0; 57.4) 66 46.4 (42.2; 50.7) 
Follow-up 23 51.7 (47.0; 56.3) 43 50.6 (47.0; 54.2) 
              
Bodily pain Baseline 30 54.5 (52.0; 57.1) 68 49.6 (47.2; 52.1) 
Follow-up 22 54.9 (51.5; 58.2) 45 53.5 (50.8; 56.2) 
              
General health Baseline 29 47.2 (43.0; 51.4) 67 45.0 (42.0; 47.9) 
Follow-up 22 49.8 (44.6; 55.1) 44 46.7 (43.7; 49.7) 
              
Vitality Baseline 29 51.6 (48.5; 54.7) 67 49.3 (46.5; 52.1) 
Follow-up 22 49.8 (45.9; 53.8) 44 49.4 (46.0; 52.7) 
              
Social functioning Baseline 30 51.2 (48.1; 54.2) 68 50.2 (47.8; 52.6) 
Follow-up 23 53.4 (50.5; 56.4) 45 52.5 (49.9; 55.1) 
              
Role emotional Baseline 29 50.5 (46.0; 54.9) 67 47.5 (43.3; 51.8) 
Follow-up 23 53.2 (48.6; 57.7) 43 52.5 (48.7; 56.4) 
              
Mental health Baseline 29 49.1 (45.4; 52.8) 67 49.1 (46.5; 51.8) 
Follow-up 22 51.9 (49.7; 54.1) 43 50.8 (47.6; 53.9) 
              
Summary Scores 
Physical Component Summary Baseline 28 52.8 (50.2; 55.3) 65 46.8 (43.7; 50.0) 
Follow-up 21 52.4 (49.4; 55.4) 41 50.4 (47.6; 53.2) 
              
Mental Component Summary Baseline 28 49.6 (46.1; 53.0) 65 49.6 (46.9; 52.3) 
Follow-up 21 51.3 (48.2; 54.3) 41 51.4 (48.1; 54.6) 
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Results from the analysis of covariance models. Abbreviations: CI, confidence interval; Coef, coefficient; N, number; SS, sum of squares 
 
ap-value derived from Wald tests, testing for the null hypothesis that the coefficients of respective covariables are equal to zero. 
bCoefficient derived from linear regression models involving follow-up score as independent and covariables as dependent variables. In all regression models, 
we a priori included baseline score, tolvaptan treatment, sex, age at survey and added interaction terms where appropriate. 
cReference: No Tolvaptan treatment. 
dReference: Male sex. 
eAge at survey in years (continuous variable). 
 
 
Table 3. Influence of baseline HRQoL, Tolvaptan treatment, sex and age on HRQoL during follow up 
 Covariable N SS p-valuea Coef
b
 
(95% CI) 
Physical functioning Baseline Score 
66 
1051 <0.001 0.6 (0.4; 0.8) 
 Tolvaptanc 3 0.71 0.5 (-2.2; 3.2) 
 Sexd 0.1 0.95 0.1 (-2.4; 2.5) 
 Age at surveye 58 0.12 0.1 (-0.02; 0.2) 
Role physical Baseline Score 
62 
1736 <0.001 0.4 (0.2; 0.6) 
 Tolvaptanc 31 0.59 -1.5 (-7.3; 4.2) 
 Sexd 0.001 1.00 0.01 (-5.4; 5.4) 
 Age at surveye 51 0.49 -0.1 (-0.3; 0.2) 
Bodily pain Baseline Score 
65 
1940 <0.001 0.8 (0.5; 1.1) 
 Tolvaptanc 7 0.69 -0.7 (-4.3; 2.9) 
 Sexd 123 0.10 21.5 (-3.9; 46.8) 
 Age at surveye 9 0.55 0.1 (-0.2; 0.3) 
 Baseline Score*Sexd 116 0.11 -0.3 (-0.7; 0.1) 
 Sexe*Age at surveye 9 0.65 -0.1 (-0.4; 0.2) 
General health Baseline Score 
63 
3411 <0.001 0.7 (0.5; 0.9) 
 Tolvaptand 3 0.82 0.5 (-3.7; 4.7) 
 Sexd 14 0.62 -1.0 (-5.1; 3.1) 
 Age at surveye 148 0.11 0.1 (-0.03; 0.3) 
Vitality Baseline Score 
62 
2211 <0.001 0.6 (0.4; 0.8) 
 Tolvaptanc 8 0.74 -0.8 (-5.4; 3.9) 
 Sexd 1 0.90 -0.3 (-4.7; 4.1) 
 Age at surveye 4 0.80 -0.02 (-0.2; 0.2) 
Social functioning Baseline Score 
66 
650 0.001 0.4 (0.2; 0.6) 
 Tolvaptanc 2 0.85 -0.4 (-4.4; 3.7) 
 Sexd 152 0.11 -3.1 (-7.0; 0.7) 
 Age at surveye 17 0.59 0.05 (-0.1; 0.2) 
Role emotional Baseline Score 
62 
711 0.02 0.3 (0.1; 0.5) 
 Tolvaptanc 25 0.65 1.4 (-4.6; 7.4) 
 Sexd 50 0.52 -1.9 (-7.6; 3.9) 
 Age at surveye 4 0.85 0.02 (-0.2; 0.3) 
Mental health Baseline Score 
61 
1244 <0.001 0.5 (0.3; 0.7) 
 Tolvaptanc 43 0.40 1.8 (-2.5; 6.1) 
 Sexd 1 0.90 0.3 (-3.9; 4.4) 
 Age at surveye 16 0.61 0.05 (-0.1; 0.2) 
 
 
 
   
Summary Scores  
   
 Baseline Score 58 1379 <0.001 0.5 (0.3; 0.7) 
Physical Component 
Summary Tolvaptanc  4 0.76 -0.6 (-4.6; 3.4) 
 Sexd  66 0.24 2.2 (-1.5; 5.8) 
 Age at surveye  18 0.53 0.05 (-0.1; 0.2) 
 Baseline Score 58 1116 <0.001 0.5 (0.2; 0.7) 
Mental Component 
Summary Tolvaptanc  3 0.84 0.5 (-4.1; 5.1) 
 Sexd  46 0.41 -1.8 (-6.3; 2.6) 
 Age at surveye  34 0.48 0.07 (-0.1; 0.3) 
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Table 4: Mean scores of kidney-specific health concerns of AKPKD patients with and without Tolvaptan treatment at baseline and follow-up  
 
  
Time point 
Tolvaptan   No Tolvaptan   
  
N Mean scores  (95% CI)   N 
Mean scores  
(95% CI)   
Symptom/ Problem Baseline 29 89.5 (86.2; 92.8) 67 83.7 (80.5; 86.9) 
Follow-up 23 86.3 (81.8; 90.7) 47 83.7 (79.9; 87.5) 
              
Effects of kidney disease Baseline 30 95.1 (92.8; 97.4) 68 90.6 (88.0; 93.3) 
Follow-up 23 92.6 (89.4; 95.9) 45 92.9 (89.0; 96.7) 
              
Burden of kidney disease Baseline 29 86.9 (81.7; 92.0) 66 80.2 (74.7; 85.7) 
Follow-up 23 81.5 (75.7; 87.4) 47 83.9 (77.8; 90.0) 
              
Work status Baseline 29 94.8 (87.0; 102.6) 65 86.9 (79.6; 94.3) 
Follow-up 23 100.0 (100.0; 100.0) 46 87.0 (78.4; 95.5) 
              
Cognitive function Baseline 30 88.2 (83.5; 93.0) 68 82.8 (78.8; 86.8) 
Follow-up 23 88.7 (84.9; 92.5) 46 85.1 (81.0; 89.1) 
              
Quality of social interaction Baseline 30 82.0 (76.9; 87.1) 68 82.6 (79.4; 85.9) 
Follow-up 23 81.6 (76.5; 86.7) 47 81.7 (77.6; 85.8) 
              
Sexual function Baseline 29 89.2 (81.0; 97.4) 63 84.1 (77.7; 90.6) 
Follow-up 22 88.6 (78.2; 99.0) 46 85.9 (78.4; 93.4) 
              
Sleep Baseline 30 68.2 (62.2; 74.2) 68 70.1 (65.8; 74.4) 
Follow-up 23 66.8 (60.1; 73.6) 47 70.9 (64.5; 77.3) 
              
Social support Baseline 30 76.1 (67.4; 84.9) 68 69.9 (62.8; 76.9) 
Follow-up 23 81.9 (75.4; 88.4) 47 75.9 (67.8; 84.0) 
              
Patient satisfaction Baseline 24 68.8 (56.8; 80.7) 55 70.9 (65.5; 76.3) 
Follow-up 21 79.4 (72.6; 86.1) 45 71.5 (66.4; 76.6) 
              
Overall health Baseline 29 83.1 (79.6; 86.6) 65 77.2 (73.2; 81.3) 
Follow-up 23 82.2 (77.7; 86.7) 47 78.3 (74.1; 82.5) 
              
Results from multivariable linear regression. Abbreviations: CI, confidence interval;  
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Table 5. Influence of baseline health concern, Tolvaptan treatment, sex and age on health concern during follow up 
 Covariable N SS p-valuea Coefb (95% CI) 
Symptom/ Problem 
 
Baseline Score 
64 
4800 <0.001 0.8 (0.6; 0.9) 
Tolvaptanc 217 0.06 -4.1 (-8.4; 0.2) 
Sexd 287 0.03 -4.4 (-8.4; -0.4) 
Age at surveye 7 0.73 -0.03 (-0.2; 0.1) 
 
Effects of kidney disease 
Baseline Score 
66 
763 0.01 0.4 (0.1; 0.7) 
Tolvaptanc 4 0.85 -2.9 (-32.8; 27.0) 
Sexd 15 0.72 -1.0 (-6.4; 4.4) 
Age at surveye 208 0.07 -0.2 (-0.5; 0.02) 
Tolvaptanc#Age at surveye 0.4 0.95 0.02 (-0.6; 0.7) 
 
Burden of kidney disease 
Baseline Score 
62 
1725 <0.001 0.6 (0.3; 0.8) 
Tolvaptanc 302 0.16 47.4 (-20.0; 114.9) 
Sexd 22 0.70 -1.3 (-7.8; 5.3) 
Age at surveye 408 0.24 0.2 (-0.1; 0.5) 
Tolvaptanc#Baseline Score 19 0.73 -0.1 (-0.7; 0.5) 
Tolvaptanc#Age at surveye 1008 0.01 -1.0 (-1.8; -0.2) 
 
Work status 
Baseline Score 
59 
2591 <0.001 0.5 (0.2; 0.7) 
Tolvaptanc 177 0.28 3.7 (-3.1; 10.5) 
Sexd 231 0.22 -4.1 (-10.6; 2.5) 
Age at surveye 30 0.66 0.1 (-0.2; 0.4) 
 
Cognitive function 
Baseline Score 
65 
5428 <0.001 0.6 (0.5; 0.8) 
Tolvaptanc 30 0.47 -1.5 (-5.6; 2.7) 
Sexd 80 0.25 -2.3 (-6.2; 1.6) 
Age at surveye 6 0.76 -0.03 (-0.2; 0.1) 
 
Quality of social interaction 
Baseline Score 
66 
3827 0.009 0.6 (0.2; 1.1) 
Tolvaptanc 10 0.70 10.2 (-42.3; 62.7) 
Sexd 3 0.91 -2.4 (-45.2; 40.4) 
Age at surveye 5 0.22 0.2 (-0.1; 0.6) 
Tolvaptanc#Baseline Score 0.01 0.99 0.002 (-0.5; 0.5) 
Tolvaptanc#Sexd 16 0.68 -2.5 (-14.4; 9.4) 
Tolvaptanc#Age at surveye 47 0.48 -0.2 (-0.9; 0.4) 
Sexd#Baseline Score 46 0.48 0.2 (-0.3; 0.7) 
Sexd#Age at surveye 173 0.17 -0.3 (-0.7; 0.1) 
 
Sexual function 
Baseline Score 
60 
18117 <0.001 0.8 (0.7; 1.0) 
Tolvaptanc 135 0.33 -3.3 (-10.0; 3.4) 
Sexd 71 0.48 -2.3 (-8.7; 4.1) 
Age at surveye 124 0.35 -0.1 (-0.4; 0.1) 
 
Sleep 
Baseline Score 
66 
9637 <0.001 0.8 (0.5; 1.0) 
Tolvaptanc 571 0.11 -6.4 (-14.3; 1.6) 
Sexd 385 0.19 -5.0 (-12.6; 2.6) 
Age at surveye 36 0.69 -0.1 (-0.4; 0.3) 
 
Social support 
Baseline Score 
56 
1524 0.02 0.3 (0.04; 0.5) 
Tolvaptanc 378 0.24 5.5 (-3.9; 14.9) 
Sexd 1856 0.01 12.0 (2.8; 21.2) 
Age at surveye 528 0.17 -0.3 (-0.7; 0.1) 
 
Patient satisfaction 
Baseline Score 
52 
6232 <0.001 0.6 (0.4; 0.8) 
Tolvaptanc 777 0.03 8.6 (0.7; 16.5) 
Sexd 217 0.25 4.2 (-3.1; 11.6) 
Age at surveye 944 0.02 -0.3 (-0.6; -0.1) 
Overall health Baseline Score 
63 
3863 <0.001 0.6 (0.4; 0.8) 
 Tolvaptanc 3 0.86 -0.5 (-5.8; 4.9) 
 Sexd 128 0.24 3.0 (-2.0; 8.0) 
 Age at surveye 28 0.57 -0.1 (-0.3; 0.2) 
Results from multivariable linear regression. Abbreviations: CI, confidence interval; Coef, coefficient; N, number; SS, sum of squares. 
ap-value derived from Wald tests, testing for the null hypothesis that the coefficients of respective covariables are equal to zero. 
bCoefficient derived from linear regression models involving follow-up score as independent and covariables as dependent variables. In all regression models, we a 
priori included baseline score, tolvaptan treatment, sex, age at survey and added interaction terms where appropriate. 
cReference: No Tolvaptan treatment. 
dReference: Male sex. 
eAge at survey in years (continuous variable). 
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